ProCE Banner Activity

NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor vs Nonsteroidal Aromatase Inhibitor Alone for HR+/HER2- EBC

Conference Coverage
Slideset

NATALEE met its primary endpoint, with adjuvant ribociclib + NSAI showing significant improvement in iDFS vs NSAI alone in patients with stage II-III HR+/HER2- EBC at risk of recurrence, including those with node-negative disease.

Released: June 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.